Half-Year 2022 Financial and Clinical Trials Update
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
1L NSCLC PD-L1 TPS>50%
Phase/study
# of patients
Phase III
SKYSCRAPER-01
N=500-560
ARM A: Tiragolumab plus Tecentriq
Design
ARM B: Placebo plus Tecentriq
Primary endpoint
▪ Overall survival and progression-free survival
Stage III unresectable 1L NSCLC
Phase III
SKYSCRAPER-03
N=800
ARM A: Tiragolumab plus Tecentriq for up to 12 months
ARM B: Durvalumab for up to 12 months
■ Progression-free survival
Status
FPI Q1 2020
Recruitment completed Q3 2021
FPI Q3 2020
Study did not meet its co-primary endpoint of PFS Q2 2022
CT Identifier
NCT04294810
NCT04513925
NSCLC=Non-small cell lung cancer; ES-SCLC-Extensive stage small cell lung cancer; PD-L1-Programmed cell death-ligand 1; TPS-Tumor Proportion Score; PFS-Progression-free survival
127
Roche
OncologyView entire presentation